Clinical Trial Update: Study Evaluating Safety, Tolerability and Pharmacokinetics of Single and Multiple Dose of SAM-531 [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety, tolerability and pharmacokinetics of single and multiple doses of SAM-531 in Alzheimer's disease; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• SAM-531

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Alzheimer Disease | Phase 1 | Status: COMPLETED